Marinou, Kalliopi

Rapamycin treatment for amyotrophic lateral sclerosis: Protocol for a phase II randomized, double-blind, placebo-controlled, multicenter, clinical trial (RAP-ALS trial)

Mandrioli, J., D’Amico, R., Zucchi, E., Gessani, A., Fini, N., Fasano, A., Caponnetto, C., Chiò, A., Dalla Bella, E., Lunetta, C., et al. (2018) · Medicine

Amyotrophic Lateral Sclerosis ResearchAlzheimer's disease research and treatments

Cited by 128

Factors predicting survival in ALS: a multicenter Italian study

Calvo, A., Moglia, C., Lunetta, C., Marinou, K., Ticozzi, N., Ferrante, G. D., Scialo, C., Sorarù, G., Trojsi, F., Conte, A., et al. (2017) · Journal of Neurology

Amyotrophic Lateral Sclerosis ResearchNeurogenetic and Muscular Disorders Research

Cited by 122

Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial

Riva, N., Mora, G., Sorarù, G., Lunetta, C., Ferraro, O. E., Falzone, Y., Leocani, L., Fazio, R., Comola, M., Comi, G., et al. (2019) · The Lancet Neurology

Botulinum Toxin and Related Neurological DisordersCannabis and Cannabinoid Research

Cited by 104

Cardiovascular diseases may play a negative role in the prognosis of amyotrophic lateral sclerosis

Mandrioli, J., Ferri, L., Fasano, A., Zucchi, E., Fini, N., Moglia, C., Lunetta, C., Marinou, K., Ticozzi, N., Drago Ferrante, G., et al. (2018) · European Journal of Neurology

Amyotrophic Lateral Sclerosis ResearchAmyloidosis: Diagnosis, Treatment, Outcomes

Cited by 49